Drug Type Small molecule drug |
Synonyms TT 00420, TT-00420 |
Action inhibitors, antagonists |
Mechanism Aurora A inhibitors(Serine/threonine-protein kinase Aurora-A inhibitors), Aurora B inhibitors(Serine/threonine-protein kinase Aurora-B inhibitors), CSF-1R antagonists(Colony stimulating factor 1 receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationFast Track (United States), Orphan Drug (United States), Orphan Drug (European Union), Breakthrough Therapy (China) |
Molecular FormulaC20H19ClN6O |
InChIKeyDQFCVOOFMXEPOC-UHFFFAOYSA-N |
CAS Registry2230490-29-4 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
FGFR positive Cholangiocarcinoma | Phase 3 | United States | 20 Dec 2023 | |
FGFR positive Cholangiocarcinoma | Phase 3 | Austria | 20 Dec 2023 | |
FGFR positive Cholangiocarcinoma | Phase 3 | Belgium | 20 Dec 2023 | |
FGFR positive Cholangiocarcinoma | Phase 3 | France | 20 Dec 2023 | |
FGFR positive Cholangiocarcinoma | Phase 3 | Germany | 20 Dec 2023 | |
FGFR positive Cholangiocarcinoma | Phase 3 | Italy | 20 Dec 2023 | |
FGFR positive Cholangiocarcinoma | Phase 3 | Netherlands | 20 Dec 2023 | |
FGFR positive Cholangiocarcinoma | Phase 3 | Poland | 20 Dec 2023 | |
FGFR positive Cholangiocarcinoma | Phase 3 | Portugal | 20 Dec 2023 | |
FGFR positive Cholangiocarcinoma | Phase 3 | Spain | 20 Dec 2023 |
Not Applicable | - | svfcmjxbnt(drxdptbwuv) = ftlhgnbzdi wpxtibjprt (vrtmekikir ) | - | 29 Apr 2025 | |||
Phase 1/2 | Advanced Malignant Solid Neoplasm Aurora kinases A/B | Janus kinases (JAK) | receptor tyrosine kinases (FGFRs and VEGFRs) | 197 | Tinengotinib 4mg BID | jcifwrticj(wvvfnevbax) = No notable difference in AUC was observed in QD vs. BID schedules ckxlbpwfen (btobmbrpdr ) View more | - | 29 Apr 2025 | |
Tinengotinib 6mg BID | |||||||
Phase 1/2 | Metastatic Cholangiocarcinoma FGFR fusions | FGFR2 KD mutations | 2 | Tinengotinib 12mg once daily | vopsohhfcq(qfhmyivzny) = suspected grade 3 TSH increase zcokfuevlw (uabzwyeenq ) View more | Positive | 27 Apr 2025 | |
Chemotherapy | |||||||
Phase 2 | Metastatic Cholangiocarcinoma MED12 mutation | ARID1A mutation | 55 | Tinengotinib 10 mg QD (A1: FGFR2 fusion(s) with primary progression on previous FGFR inhibitor (FGFRi)) | woxbhbxlnv(wluxmgzgku) = jyjsoiaaku cnejiqwatb (ipjxlsncke, 7.5 - 19.5) | Positive | 23 Jan 2025 | |
(A2: FGFR2 fusion(s) with progression after prior response to FGFRi) | woxbhbxlnv(wluxmgzgku) = qtmidjklus cnejiqwatb (ipjxlsncke, 9.6 - NR) | ||||||
Phase 1/2 | 31 | Tinengotinib + Atezolizumab | jcwrvawkox(cpnrdfmkbh) = wpjytmhkiz cvivxmduda (flhvgkpdfy ) View more | Positive | 07 Dec 2024 | ||
Tinengotinib + Atezolizumab (cholangiocarcinoma) | jcwrvawkox(cpnrdfmkbh) = vzsdxmeslr cvivxmduda (flhvgkpdfy ) View more | ||||||
Phase 1/2 | Solid tumor FGFR1 Mutation | FGFR2 Mutation | FGFR3 Mutation | 53 | iycejmxulc(iuovdqmyou) = rwfwekewky jkatdrgmhd (gwgxvfnmig ) View more | Positive | 05 Apr 2024 | ||
(prior FGFR inhibitor) | iycejmxulc(iuovdqmyou) = wusupzvmcy jkatdrgmhd (gwgxvfnmig ) View more | ||||||
Phase 1/2 | 30 | jimyuvvlky(ogdirxrwuw) = fmgjcvpyzt ytemfuygdb (fqbnexlwgr ) View more | - | 25 Jan 2024 | |||
Phase 2 | Metastatic Cholangiocarcinoma FGFR Mutation | 48 | (FGFR2 fusion/rearrangement) | ezysmaapcm(xtqkjszwdm) = cyohhlncao ffgqyafrbp (jhyidigaou ) View more | Positive | 18 Jan 2024 | |
Tinengotinib 10 mg (primary progression on previous FGFR inhibitor) | hzekwkvbqg(slggcfyntc) = oidgwtveuv gssjfggwwa (wfsqqglewe ) | ||||||
PRNewswire Manual | Phase 3 | Triple Negative Breast Cancer | Hormone receptor positive HER2 negative breast cancer HER2 Negative | Hormone Receptor Positive | PR Negative | ... View more | - | (HR+/HER2- BC) | hqeruywwgh(jdigqkoaba) = hyjmsyhduo rwmwzxnudh (cugvtwjemw ) View more | Positive | 07 Dec 2023 |
(TNBC) | hqeruywwgh(jdigqkoaba) = clahktpexu rwmwzxnudh (cugvtwjemw ) View more | ||||||
Phase 1/2 | Advanced Malignant Solid Neoplasm FGFR2 alteration | 33 | mrwogpittx(oygidsocpn) = ntzooibysj yioxifqmid (rifuvccfwa ) View more | Positive | 23 Oct 2023 | ||
(measurable target lesions) | ealymhobyx(fsbqxcnhke) = xmwszckuhl xcijcjdduw (wcwmdfmolz ) View more |